Tradr 2X Long SNPS Daily ETF SNPX
Set alert
As of Apr 20, 3:59 PM ET
- YTD
- -27.56%
- 1 year
- -1.80%
- Open
- 24.50
- Prev close
- 24.26
- Mkt cap
- 3.99M
- Vol
- 11.52K
- Avg vol
- 21.96K
- EPS
- 0.88
- P/E
- 3.34
- Div yield
- 0.00%
More statistics
- Low
- 24.51
- High
- 24.75
- Forward P/E
- -0.34
- Beta
- 1.43
- Short ratio
- 0.17
- Inst. own
- 0.29%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 15, 2023
- 50-d avg
- 2.91
- 200-d avg
- 3.83
- 1y target
- 14.00
Key statistics
- Market cap
- 3.99M
- Enterprise value
- -23.82M
- Trailing P/E
- 3.34
- Forward P/E
- -0.34
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.12
- EPS (TTM)
- 0.88
- Beta
- 1.43
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 2.59M
- Total cash
- 27.41M
- Total debt
- 0
- Return on equity
- -7.50%
- Shares outstanding
- 1.36M
- Short % of float
- 0.41%
- 50-day average
- 2.91
- 200-day average
- 3.83
Analyst view
Consensus: none
Next earnings
May 15, 2023
Expected May 15, 2023. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -4.58 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -1.18 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.41 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.75 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -34.75 | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 11, 2024 | Maxim Group | up | Hold | Buy |
| Dec 19, 2022 | Maxim Group | down | Buy | Hold |
| Apr 12, 2022 | Maxim Group | init | — | Buy |
About Tradr 2X Long SNPS Daily ETF
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. The company was incorporated in 2012 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- synaptogen.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on SNPX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 0.09% | 1,271 | 3.74K | Sep 29, 2024 |
| UBS Group AG | 0.08% | 1,087 | 3.19K | Sep 29, 2024 |
| Morgan Stanley | 0.01% | 90 | 264 | Sep 29, 2024 |
| Acadian Asset Management. LLC | 0.00% | 23 | 67 | Sep 29, 2024 |
| Osaic Holdings Inc | 0.00% | 34 | 99 | Sep 29, 2024 |
| Blackrock Inc. | 0.00% | 29 | 85 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.53% | 7,146 | 21.01K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.20% | 2,740 | 8.05K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 1,927 | 5.67K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 1,748 | 5.14K | Oct 30, 2024 |